# University of Florida Clinical and Translational Research Building

**Year 4 Tax-Exempt Bond Certification Report** UF Fiscal Year 2016-2017 July 1, 2016 – June 30, 2017



# **Table of Contents**

Transmittal Document CTRB Bond Compliance	3
Executive Summary	3
Changes in Method from Year 1	4
Issues Going Forward	4
CTRB Compliance Report	5
General Background	5
Definitional Issues	5
CTR Building Occupants and Users	6
Space as Related to Program Activity	6
Grant and Research Project Activity Types	7
The Compliance Review Process	8
CTRB Bond Certification Process	9
Diagram 1. Map of Revenue Zones for CTRB Bond Certification	9
Sponsored Research (Red Zone)	9
Data Collection Overview	9
Algorithm	10
Other Support (Blue Zone)	11
Data Collection Overview	11
Blue Zone 2 Algorithm	11
Clinical Research Center (Black Zone) & Shands Pharmacy (Olive Zone)	12
CTRB Bond Certification Results Summary 2016	12
Table 1: Summary data by Zone (2016)	12
Table 2: square footage by building occupant (2016)	12
Table 3: Blue Zones 1 & 2 Fund Code Classification	13
Table 4: Safe Harbor Designation Summary from DSP (2016)	15
Table 5: Sponsors in "All Other Sources" Category (2016)	15
Table 6: Summary of Survey Results by Contract Principal Investigator (2016)	15

## **Transmittal Document CTRB Bond Compliance**

August 3, 2017

## **Executive Summary**

Attached please find the report required by the Tax Exempt Bond financing agreement for the Clinical Trials Research Building (CTRB) dated March 31, 2011. This is the fourth report in a cumulative 20 year series of reports to demonstrate that the vast preponderance (90%) of the activity of the CTRB is dedicated to public benefit.

This report is the summary of the annual process to define and categorize "research revenues" accumulated through the use of the CTRB and classify the benefits derived as "good" (public benefit) or "bad" (private benefit). Executives from the University Health Science Center, Legal Affairs and Bond Compliance were involved as well as senior scientists and department and institute managers with activities in the building. Note that the revenue was calculated in four zones were then combined into an overall amount. The process and definitions are fully described in body of the report (pages 9-17)

By the method described in the report, we calculated that the cumulative ratio of good (public) benefit to total "research revenue" for the year 2014-2017 years to be 90.0%, the percent of good use was 89.5% for 2014, 90.9% for 2015, 89.2% for 2016, and 90.1% for 2017.. This cumulative percentage good use is equal to the 90% specified in the Tax Exempt Bond financing agreement for the Clinical and Translational Research Building.

	Total Research Revenue	Amount in CTRB	Good Use	Bad Use	% Good Use
2014 Overall	\$96,719,030	\$43,404,982	\$38,849,593	\$4,555,390	89.5%
2015 Overall	\$151,280,706	\$70,139,419	\$63,753,083	\$6,386,336	90.9%
2016 Overall	\$168,767,359	\$82,959,788	\$74,013,059	\$8,946,729	89.2%
2017 Overall	\$212,777,908	\$148,690,020	\$134,025,899	\$14,664,120	90.1%
Cumulative Total for 2014-2017	\$629,545,003	\$345,194,209	\$310,641,635	\$34,552,575	90.0%

2017	Total Research Revenue	Amount in CTRB	Good Use	Bad Use	% Good Use
Red Zone: Sponsored Research	\$197,803,469	\$140,143,298	\$126,884,664	\$13,258,634	90.5%
Blue Zone 1: High Occupancy Depts	\$10,049,302	\$6,430,362	\$5,548,556	\$881,806	86.3%
Blue Zone 2: Low Occupancy Depts	\$3,890,681	\$1,081,903	\$991,307	\$90,596	91.6%
Black Zone: Clinical Research Center	\$1,034,456	\$1,034,456	\$601,372	\$433,084	58.1%
Total	\$212,777,908	\$148,690,020	\$134,025,899	\$14,664,120	90.1%

### **Changes in Method from Year 3**

As of July 1, 2016 the source of all awards data is the UFirst system. This system change required some minor changes in programming. This system assigns all Sponsors to a category, and does not have an "Other Sponsor type", as a result Table 5: Sponsors in "All Other Sources" Category has no content and will be discontinued beginning next year.

In previous years, the supporting Red Zone tables (Tables 4, 5, and 6) did not include information about the extra studies added by the investigators in the Red Zone Survey. These extra studies were included in all calculations related to the bond certification, and their omission in the display tables does not change the good and bad use percentages previously reported. The extra studies are included in the supplemental tables 4 and 6 in this report.

As of July 1, 2015, Investigational pharmacy services were billed directly as the Clinical Research Center (CRC) service. As a result the investigational pharmacy services will be reported as part of the CRC (Black Zone), the "Olive Zone" will no longer be reported as a separate category.

## **Issues Going Forward**

The collection of the space survey for UF has an official deadline in the fall of each year. This year the staff responsible for space data collection were instructed by the senior management of UFHealth to complete the space data collection for the CTRB by May 30, 2017. The data used in this report were extracted on June 2, 2017 from the space survey database, allowing us to start and complete the bond certification process by the reporting deadline. We should continue to require that the space survey for the CTRB North Wing be completed by June 4 or earlier to meet the Bond Compliance Reporting deadline.

## **CTRB Compliance Report**

## **General Background**

The University of Florida Clinical and Translational Research Building (CTRB) serves as the *headquarters* for clinical and translational science at UF. It is home to the Clinical and Translational Science Institute (CTSI) which conducts on-site research and is also the hub of a statewide network that aims to bring "the benefits of research to more than 9 million patients in all of Florida's 67 counties" (see <a href="CTSI">CTSI</a> website).

The north wing of the CTRB was funded with tax-exempt bonds. The bonds have specific covenants requiring that the vast preponderance of "research revenue" generated through the use of the building over the 20-year life of the bonds be in the clear public benefit. More precisely the ratio of "qualified research revenue" (that is clearly in the public benefit) to total research revenue must exceed 90%. In addition to this qualified research condition, there are restrictions on other purely commercial activities such as bookstores or kiosks.

Note: Though the north wing of the CTRB physically adjoins with the south wing, home to the UF Institute on Aging headquarters, the south wing was constructed with a NIH grant and is specifically excluded from any CTRB covenants in the north wing.

### **Definitions**

**Research revenue** is defined as revenue from "research arrangements" ("contracts, grants, etc. with a state or local governmental unit, a Federal Sponsor or any other third party"). The term "research revenue" is not widely used within academic medicine. Interpreted broadly, it was construed to subsume several more common concepts such as research funding, research awards and research support. It may also subsume all or part of traditional categories, such as cost recoveries and gifts.

Note: The broadest (most conservative) definition of research revenue has been used in the report, which specifically includes grants and contracts that are routed through the Office of Research, and general support for other research activities that are not funded through an "official" contract or grant.

**Basic Research** The compliance definition of "basic research" includes any original investigation for the advancement of scientific knowledge not having a specific commercial objective. This very broad definition includes clinical research and other research activities that do not have a specific commercial objective.

Note: The broadest (most conservative) definition of basic research has been used in the report to include all research activities – translational, clinical and health services.

**Laboratories** The term "laboratories" which is frequently used in the compliance agreement is difficult to precisely apply to research involving human subjects where a relatively small proportion of the research activity is conducted in "wet labs" and much work requires both clinical and research venues. Translational research is frequently conducted in multiple venues in multiple buildings and even at

multiple universities. The rate limiting factor in clinical research is often access to appropriate subjects rather than access to highly capitalized laboratory facilities.

Note: The broadest (most conservative) definition of laboratories has been used in the report and includes the Clinical Research Center, an "auxiliary" that may be considered analogous to a core laboratory in a wet lab setting and certain support units such as Biostatistics.

## **CTR Building Occupants and Users**

Four general levels of occupants and users have been included in the report.

Major Building Tenants: Research institutes and university departments that are headquartered in the CTRB and have substantial programmatic presence in the building. These are the Clinical and Translational Science Institute (13,066 square feet), the Departments of Biostatistics (5,986 square feet) and Department of Epidemiology (4,694 square feet). These occupants are specifically referenced in the compliance agreement. (see Table 2)

**Minor Building Tenants**: These include the research groups specifically referenced in the compliance agreement. Research groups are not in themselves organizational units of the university, but they are: 1-members of university departments that are not headquartered in the CTRB, 2-have significant translational research activities in the CTRB, and 3-collaborate with other CTRB occupants. The Department of Health Outcomes and Policy, which is headquartered outside the CTRB, is the largest of this group, and the Department of Medicine has several of these research groups or "colonies".

**Occasional and infrequent users:** These are individual investigators and research associates who are not included as members of major or minor tenants but who may use services of the Clinical Research Center (CRC) or other building occupants. In nearly all cases these are university faculty and staff.

**Clinical Research Center (CRC):** This special category was created to consider the CRC located on the first floor which is a CTSI service auxiliary that recovers the preponderance of its direct costs through transfer payments and fees charged to facility users.

Note: The same compliance standard was used for each level of user or building occupant, but data collection methods were adapted to their unique circumstances.

## **Space as Related to Program Activity**

Grants and projects activity are often not restricted to individual spaces or buildings, the actual conduct of the research studies can occur across a wide number of institutions. Many projects and programs have substantial activities that reach far beyond the CTRB and even the campus. In some instances, CTRB occupants and users may be at the "project level", such as a biostatistician supporting a grant, so only a small portion of the overall activity related to its parent grant or contract occurs in the CTRB. In other instances, the large majority of the grant activity occurs in the CTRB.

Note: The university's annual space survey interviews building occupants and users of individual spaces within the building and details the projects, grants and other forms of support that are associated with

each space. The CTRB report accumulates activity from grants and projects that were identified in the space survey as having <u>activity in the CTRB</u>.

## **Grant and Research Project Activity Types**

Financial accounting structures may be different depending on the formality of the research project and the external reporting requirements. The compliance review considered four general categories of grants and research activity.

#### **Extramural Grants and Contracts**

All major externally funded grants and contracts are identified in the UFirst Awards Database and include contact information for the Award Principle Investigators (PI). Awards can contain one or more projects.

Note: Each Award PI (n=118) was surveyed about the Awards (n=327) whose related projects were identified in the space survey. The award PI was asked to estimate the proportion of the overall award activity that occurred in the CTRB. This ratio was applied to the overall award to determine the amount of research revenue appropriately associated with the CTRB.

#### **Other Defined Research Projects**

These may be sponsored by foundation, individuals, businesses associations or others.

Note: Depending on the financial structure, these activities could be treated as major grants (above) or as projects that were accounted through a grouping of associated "fund codes" that identify streams of support that could be characterized as revenue. Deliberate attention was paid to avoid any double counting of revenue or support.

#### **Departmentally Sponsored Research**

These may be startup funding for new investigators, seed funding during grant development or other activities deemed to foster research or the growth of research capability that is directly associated with an individual researcher or research group.

Note: These activities are not well compartmentalized in the accounting system and were categorized by groupings of fund codes.

#### **General Research Support Activities and Services**

These activities may provide necessary professional skills, facilities, software or a wide range of general support for researchers, research grants and the "research environment". In most cases "fund codes" were used to characterize support.

Note: These activities were reported from departmental records and may include all direct support for programs completely housed in the CTRB.

## **The Compliance Review Process**

The compliance review process involved three distinct phases: identification, apportionment and disclosure.

### 1) Identification of CTRB activities

Building use was identified in concert with the university's annual space survey.

Note: All projects with <u>any</u> CTRB involvement were identified during the space survey. Activities that could be directly identified with a principle investigator were treated as major grants and subject to the principle Investigator survey. Research activities that are not counted as "sponsored research" in the university's space survey were included in the department review process. These two methods were thoroughly checked to avoid duplication of accounting and the results were combined in the final compliance accounting.

#### 2) Apportionment of Activity

Apportionment is the basis by which research activity is divided into the CTRB and non CTRB portions. Three basic approaches to apportionment were needed to complete the compliance review process: grant activity apportionment (PI), programmatic apportionment (Major Tenants and CRC) and individual effort apportionment (Minor Tenants and infrequent users).


Note: Since apportionment requires judgment calls, the responsible individual with "the best view" of the distribution of activity in each situation was interviewed. For major grants the PI was surveyed directly though in some cases the grant administrator or project PI was allowed to submit a proxy response. Department heads or administrators were required to complete budget worksheets for revenue identified as general support. In a few instances of minor occupants and infrequent users, nonsponsored research categories, such as "department research" and "other support activities", from the space survey were examined to determine the best basis for CTRB use.

#### 3) Disclosure and Safe Harbors

The UF Office of Research applied the Stanford University safe harbor rules to review and classify UF intellectual property right for funded research. Fund codes were used to classify the non-sponsored research activities as "good" or "bad" use.

## **CTRB Bond Certification Process**

Diagram 1. Map of Revenue Zones for CTRB Bond Certification



## **Sponsored Research (Red Zone)**

#### **Data Collection Overview**

- Obtain list of PeopleSoft (PS) project numbers and corresponding CTRB room numbers reported in CTRB space survey
- Merge PS project numbers with UFirst Awards History database to obtain additional data fields such as award amount, Award PI, etc.
- Merge Award PI UFID to UF Directory to obtain Contract PI email
- Roll-up PS projects to the contract (aka "parent) level and load contract information to Qualtrics survey (see table 3)
- Field Qualtrics survey to collect the percentage of Award Activity occurring in the North wing of the CTRB from the Award PI.

 Apply "% activity in CTRB" to total award amount (less sub-contracts) to calculate qualified research revenue for sponsored activities in CTRB (i.e. grants or contracts with a PS project number reported in space survey)

## **Algorithm**

**Total Award:** Amount in Dollars Awarded for Fiscal Year 2013-14 Source: UF Office of Research – UFirst Awards History Data

**PctCTRB:** Percentage of Award Activity in the CTRB Source: Principal Investigator Qualtrics Survey

CTRB\_Activity\_Amount: Amount in Dollars of Activity in CTRB

Calculated: Adjusted Award \* PctCTRB

 $\textbf{Safe\_Harbor\_Use:} \ 1\text{--meets requirements for "Good Use"}, \ 0\text{--Otherwise}$ 

Source: Contract Review by Office of Research

CTRB\_Good\_Use: Amount in Dollars of "Good Use" Activity in CTRB

Calculated: CTRB\_Activity\_Amount \* Safe\_Harbor\_Use

Good Use Proportion: Percentage of CTRB activity assigned to "Good Use"

Calculated: CTRB\_Good\_Use / CTRB\_Activity\_Amount

Good\_Use Proportion: (Total\_Award ) \* PctCTRB \* Safe\_Harbor\_Use

(Total\_Award) \* PctCTRB

## **Other Support (Blue Zone)**

#### **Data Collection Overview**

- Purpose: identify additional support that should count as "qualified research revenue" but is not assigned a PeopleSoft project number from the Office of Research (i.e. 171 funds)
- Data process divided into two groups based on square footage (see table 1):
  - o **Blue Zone 1:** Departments that occupy >14% of the north wing will review department operating budget for the reporting year and submit the following in an excel file:
    - Identify support for research activity that is not funded by grants or contracts
    - Apportion the % of activity in the building
    - Apply % activity to budgeted amount (this is amount that counts as QRR)
    - Classify good vs. bad using fund code definitions (see table 4)
  - Blue Zone 2: Departments that occupy <9% of the north wing will use "department research" and "OSA" categories in the space survey to:
    - Use DR and OSA % as proxy for % activity in the building
    - Use primary room occupant earnings as proxy for qualified research revenue
    - Classify good vs. bad using fund code definitions (see table 4)

### **Blue Zone 2 Algorithm**

Salary Paid: Amount paid in Salary for time period

Fringe Paid: Amount of Fringe Benefits paid in time period

Fund\_Mask: 1 if Fund Code is "Good" Use, 0 otherwise

Omit Rec: 1 if record is to be Omitted (O Otherwise) Added to remove funds counted in RedZone.

**DR\_11:** Proportion of Payment attributable to department research Source: UF Payroll File

**OSA\_17:** Proportion of Payment attributable to other sponsored activities Source: UF Payroll File

**Qualified Total Paid:** Amount of Salary and Fringe Paid classified as Qualified Revenue Calculated (Salary\_Paid+Fringe\_Paid) X (DR\_11\_1 + OSA\_17\_1)

Qualified Good: Total Salary & Fringe Paid where Fund\_Mask=1 (Good Use Funds)

Calculated: Qualified Total Paid X Fund Mask

**Proportion of Good Use:** Percentage of Activity in CTRB Attributed to "Good" Use Calculated: **Qualified Good / Qualified Total Paid** 

Using only records where Omit\_Rec=0, calculate:

(Salary\_Paid + Fringe\_Paid)\*(DR\_11 + OSA+17)\*Fund\_Mask

(Salary\_Paid + Fringe\_Paid)\*(DR\_11+ OSA+17)

## **Clinical Research Center (Black Zone)**

Revenues generated from Clinical Research Center (CRC) that are not identified in the "grants and contracts" or "other support" data collection efforts are also are classified as Good / Bad Use based on Sponsor type or determination by the Division of Sponsored programs. Investigational Pharmacy Service previously reported as the "Olive Zone" are now included in the CRC (Black Zone) revenues.

## **CTRB Bond Certification Results Summary 2017**

Table 1: Summary data by Zone (2017)

2017	Total Research Revenue	Amount in CTRB	Good Use	Bad Use	% Good Use
Red Zone: Sponsored Research	\$197,803,469	\$140,143,298	\$126,884,664	\$13,258,634	90.5%
Blue Zone 1: High Occupancy Depts	\$10,049,302	\$6,430,362	\$5,548,556	\$881,806	86.3%
Blue Zone 2: Low Occupancy Depts	\$3,890,681	\$1,081,903	\$991,307	\$90,596	91.6%
Black Zone: Clinical Research Center	\$1,034,456	\$1,034,456	\$601,372	\$433,084	58.1%
Total	\$212,777,908	\$148,690,020	\$134,025,899	\$14,664,120	90.1%

Table 2: square footage by building occupant (2017)

Occupant Department	Total Sq Ft	% of Total	Occupant Type
MD-CTSI	13066.883	34.9%	Major
PHHP-COM EPIDEMIOLOGY	5986.1009	16.0%	Major
PHHP-COM BIOSTATISTICS	4694.6399	12.5%	Major
MD-HEALTH OUTCOMES AND			
POLICY	4309.7773	11.5%	Major
MD-MEDICINE	2112.3383	5.6%	Minor
HP-PHYSICAL THERAPY	2222.1172	5.9%	Minor
MD-PEDIATRICS	1794.1591	4.8%	Minor
HA-ADMINISTRATION	1209.5977	3.2%	Minor
DN-COMMITY BASED PROGRAMS	894.1248	2.4%	Minor
PPD-OPER HC SYSTEMS & ADMIN	832.8136	2.2%	Minor
PH-PHARMTHERAPY TRNSL RSCH	198.5302	0.5%	Minor
MD-COM DEAN'S OFFICE	114.4105	0.3%	Minor

Table 3: Blue Zones 1 & 2 Fund Code Classification

Fund_Codes	Fund Code Description	Good/Bad?
101	E&G-GEN REV - MAIN CAMPUS	GOOD
	State Appropriations	
102	E&G-GEN REV – HSC	GOOD
	State Appropriations	
106	E&G-GEN REV UF ON-LINE	GOOD
	State Appropriations – UF Online	
107	E&G-GEN REV-PREEMINENCE	GOOD
	This fund will be used to budget and track expenditures from	
	State Preeminence funds.	
143	AUX - DOCE FUND	GOOD
	Division of Continuing Education (DCE)	
149	AUX - OTHER FUNDS	BAD
	Current unrestricted fund used to account for sales of goods	
	and services to faculty, staff and students.	
151	AUX - WORKING CAPITAL TR FD	BAD
	Current unrestricted fund used to account for the auxiliary-	
	related financial transactions of the Physical Plant Division.	
171	TFRS FR COMPONENTS	GOOD
	A current restricted fund used to account for monies	
	received from the University of Florida's component units	
	(e.g DSOs).	
175	UF STRATEGIC FUND NONRESEARCH	BAD
	This fund was established to support strategic initiatives that	
	are not restricted for research.	
179	OTHER MISC DONATIONS	GOOD
	A current unrestricted fund used to record incidental	
	revenues from various unrestricted sources. There are no	
	external requirements placed on the money in this fund.	
182	IFAS - EXT SVC INCIDENTAL TF	BAD
	A current unrestricted fund established to support the	
	Extension function of UF/IFAS. Revenues are from the sale of	
	Extension publications, products, and programs, and fees for	
101	diagnostic testing.  STUDENT GOVT FUNDS	DAD
191	A current unrestricted fund established for the collection of	BAD
	student activity fees.	
194	PAYROLL FUND	GOOD
194	A 'holding' fund used by University Payroll and University	GOOD
	Tax Services, to process payroll and tax related transactions	
	that cannot be immediately posted to the appropriate cost	
	center. These deposits and expenses are distributed to the	
	appropriate cost center after they are reconciled.	
201	C&G - FEDERAL RESTRICTED	REMOVE
	A restricted fund used to account for Federal and Federal	NEIVIO V L
	flow thru contracts and grants related to research, training,	
	now this contracts and grants related to research, training,	

Fund_Codes	Fund Code Description	Good/Bad?
	or other sponsored activities.	
209	C&G - OTHER RESTRICTED	REMOVE
	A restricted fund used to record contracts and grants from	
	State, corporate, and private sources for research, training,	
	and other sponsored activities.	
211	C&G - RETURNED OVERHEAD	GOOD
	A restricted fund used to accumulate and manage all the	
	earned overhead from research projects. These funds are to	
	be used only in support of other research or sponsored	
	training programs, as directed in Section 1004.22(5), Florida	
	Statutes.	
212	C&G - RESIDUAL FUNDS	GOOD
	A restricted fund used to record money from miscellaneous	
	donors and earned residuals from research projects. These	
	funds are to be used only in support of other research or	
	sponsored training programs, as directed in Section	
	1004.22(5), Florida Statutes and by UF Policy.	
213	UFRF ALLOCATIONS	GOOD
	A restricted fund used to accumulate and manage deposits	
	from the direct support organization, UF Research	
	Foundation (UFRF). These funds are restricted and are to be	
	used in support of other research or sponsored training	
	programs, as directed by UFRF.	
214	C&G NON FED CLINICAL TRIALS	BAD
	The C&G Non Fed Clinical Trials fund is a restricted fund that	
	was established to support the University's Industry	
	Sponsored Clinical Trial Business.	
221	IFAS - EXP STAT FEDERAL TF	GOOD
	A restricted fund used to record money from the Hatch Act	
	Federal Appropriation. These funds are restricted to the	
	research function	
279	RESTRICTED INCIDENTAL FUND	GOOD
	A current restricted fund to place incidental revenues that	
	are restricted to a specific department or purpose.	

Table 4: Safe Harbor Designation Summary from DSP (2016)

Prime Sponsor Type	Good Use	Bad Use	Total
Federal Agencies	153	0	153
Corporations/Company For Profit	44	58	102
Non Profit Organizations	35	3	38
University of Florida	14	0	14
UF DSO and Related HSC Affiliated	12	0	12
University of Fla Foundation	7	0	7
Florida Government	6	0	6
Miscellaneous	2	0	2
Non-Florida Government	2	0	2
Universities	2	0	2
Total Number of Awards	277	61	338

Table 5: Sponsors in "All Other Sources" Category (2017)

Sponsor Name	Number of Awards	Award Amount
The UFirst System was in operation on J	uly 1, 2016, and cove	rs the entire set of
data used in the 2017 CRTB Bond Certifi	cation. The UFirst sy	stem assigns sponsor
Categories to all Sponsors		

**Table 6: Summary of Survey Results by Contract Principal Investigator (2017)** 

Contract PI Name	Number of	Amount in CTRB	Good	Bad Revenue	Percent
	Awards		Revenue		Good
Albanese-O'Neill, Anastasia	1	\$20,860	\$20,860	\$0	100.0%
Atkinson, Mark	1	\$1,609	\$1,609	\$0	100.0%
Bihorac, Azra	1	\$0	\$0	\$0	0.0%
Bishop, Mark	1	\$98,770	\$98,770	\$0	100.0%
Brady, Linda	1	\$37,754	\$37,754	\$0	100.0%
Brakenridge, Scott	1	\$0	\$0	\$0	0.0%
Bril, Fernando	1	\$20,000	\$20,000	\$0	100.0%
Brumback, Babette	1	\$158,619	\$158,619	\$0	100.0%
Bulitta, Jurgen	1	\$291,722	\$291,722	\$0	100.0%
Byrne, Barry	39	\$3,429,121	\$1,140,509	\$2,288,612	33.3%
Cabrera, Roniel	1	\$0	\$0	\$0	0.0%
Campbell Thompson, Martha	1	\$46,555	\$46,555	\$0	100.0%
Cavallari, Larisa	1	\$306,221	\$306,221	\$0	100.0%
Chen, Xinguang	4	\$2,155,770	\$2,155,770	\$0	100.0%
Chen, Zhiguo	1	\$17,578	\$17,578	\$0	100.0%
Cheng, Ting-Yuan	1	\$88,083	\$88,083	\$0	100.0%

Contract PI Name	Number of	Amount in CTRB	Good	Bad Revenue	Percent
	Awards		Revenue		Good
Clark, Virginia	2	\$59,552	\$47,978	\$11,574	80.6%
Cohen, Ronald	2	\$161,616	\$161,616	\$0	100.0%
Conesa Cegarra, Ana	1	\$0	\$0	\$0	0.0%
Conrad, Kirk	1	\$177,152	\$177,152	\$0	100.0%
Cook, Robert	7	\$1,717,217	\$1,717,217	\$0	100.0%
Corti, Manuela	8	\$445,842	\$445,842	\$0	100.0%
Cottler, Linda	7	\$3,263,550	\$3,140,700	\$122,850	96.2%
Cusi, Kenneth	4	\$1,440,089	\$30,000	\$1,410,089	2.1%
Datta, Somnath	2	\$250,308	\$250,308	\$0	100.0%
Datta, Susmita	2	\$31,399	\$31,399	\$0	100.0%
Delcher, Philip	5	\$634,855	\$634,855	\$0	100.0%
Devidas, Meenakshi	1	\$0	\$0	\$0	0.0%
Ding, Mingzhou	2	\$9,736	\$9,736	\$0	100.0%
Ebner, Natalie	1	\$3,509	\$3,509	\$0	100.0%
Efron, Philip	1	\$0	\$0	\$0	0.0%
Esser, Karyn	1	\$0	\$0	\$0	0.0%
Fillingim, Roger	8	\$4,559,165	\$4,559,165	\$0	100.0%
Firpi-Morell, Roberto	7	\$374,999	\$82,764	\$292,235	22.1%
Forbes, Sean	2	\$40,201	\$40,201	\$0	100.0%
Forsmark, Christopher	2	\$210,997	\$210,997	\$0	100.0%
George, Steven	1	\$80,364	\$80,364	\$0	100.0%
Ghayee, Hans	1	\$20,977	\$0	\$20,977	0.0%
Golde, Todd	1	\$1,435,013	\$1,435,013	\$0	100.0%
Gurka, Kelly	1	\$47,558	\$47,558	\$0	100.0%
Gurka, Matthew	1	\$206,150	\$206,150	\$0	100.0%
Haller, Michael	13	\$4,618,835	\$4,603,780	\$2,906	99.7%
Harrison, Jeffrey	1	\$87	\$87	\$0	100.0%
Hegland, Karen	1	\$990	\$990	\$0	100.0%
Hogan, William	4	\$646,859	\$646,859	\$0	100.0%
Horgas, Ann	1	\$21,679	\$21,679	\$0	100.0%
Jeong, Kwang	1	\$8,749	\$8,749	\$0	100.0%
Johnson, Julie	1	\$480,029	\$480,029	\$0	100.0%
Kairalla, John	1	\$72,175	\$72,175	\$0	100.0%
Kang, Peter	1	\$10,517	\$0	\$10,517	0.0%
Karst, Stephanie	1	\$0	\$0	\$0	0.0%
Khoshbouei, Habibeh	2	\$10,429	\$10,429	\$0	100.0%
Kim, Jae	1	\$4,421	\$4,421	\$0	100.0%
Lawrence, Robert	2	\$16,900	\$16,900	\$0	100.0%
Li, Qiuhong	1	\$655	\$655	\$0	100.0%
Liang, Faming	1	\$15,834	\$15,834	\$0	100.0%

Contract PI Name	Number of	Amount in CTRB	Good	Bad Revenue	Percent
	Awards		Revenue		Good
Licht, Jonathan	3	\$107,300	\$107,300	\$0	100.0%
Lott, Donovan	1	\$14,339	\$14,339	\$0	100.0%
Lucero, Robert	1	\$3,237	\$3,237	\$0	100.0%
Mai, Volker	2	\$242,911	\$242,911	\$0	100.0%
Maldonado Molina, Mildred	4	\$178,790	\$178,790	\$0	100.0%
Modave, Francois	2	\$206,778	\$206,778	\$0	100.0%
Moldawer, Lyle	1	\$0	\$0	\$0	0.0%
Moore, Frederick	3	\$49,223	\$49,223	\$0	100.0%
Morelli, Giuseppe	9	\$459,538	\$40,617	\$418,921	8.8%
Morris, John	3	\$0	\$0	\$0	0.0%
Moseley, Ray	1	\$2,626	\$2,626	\$0	100.0%
Muller, Keith	3	\$527,801	\$527,801	\$0	100.0%
Nelson, David	29	\$66,696,294	\$65,367,986	\$1,328,308	98.0%
Neu, Josef	1	\$3,924	\$3,924	\$0	100.0%
Nittrouer, Susan	1	\$850	\$850	\$0	100.0%
Nixon, Sara	2	\$3,918	\$3,918	\$0	100.0%
O'Dell, Walter	1	\$1,689	\$1,689	\$0	100.0%
Odedina, Folakemi	1	\$146	\$146	\$0	100.0%
Okun, Michael	1	\$864	\$864	\$0	100.0%
Patten, Carolynn	1	\$0	\$0	\$0	0.0%
Pemberton, Donald	1	\$18,979	\$18,979	\$0	100.0%
Pepine, Carl	1	\$630	\$630	\$0	100.0%
Ploetz, Randy	1	\$0	\$0	\$0	0.0%
Price, Catherine	1	\$5,879	\$5,879	\$0	100.0%
Prins, Cindy	1	\$0	\$0	\$0	0.0%
Prosperi, Mattia	3	\$122,547	\$122,547	\$0	100.0%
Qiu, Peihua	2	\$318,204	\$318,204	\$0	100.0%
Riley, Joseph	2	\$1,368,569	\$1,368,569	\$0	100.0%
Ross, Kathryn	1	\$25,782	\$25,782	\$0	100.0%
Sadasivan, Donna	1	\$2,038	\$2,038	\$0	100.0%
Salloum, Ramzi	5	\$143,736	\$143,736	\$0	100.0%
Scarpace, Philip	1	\$0	\$0	\$0	0.0%
Schatz, Desmond	7	\$1,647,338	\$1,635,671	\$11,667	99.3%
Shenkman, Elizabeth	18	\$22,293,909	\$17,814,658	\$4,479,251	79.9%
Shorr, Ronald	1	\$0	\$0	\$0	0.0%
Silverstein, Janet	1	\$3,480	\$3,480	\$0	100.0%
Smith, Barbara	5	\$225,406	\$224,720	\$686	99.7%
Solberg, Laurence	1	\$1,525	\$0	\$1,525	0.0%
Sonke, Jill	1	\$0	\$0	\$0	0.0%
Stacpoole, Peter	1	\$506	\$506	\$0	100.0%

Contract PI Name	Number of	Amount in CTRB	Good	Bad Revenue	Percent
	Awards		Revenue		Good
Staras, Stephanie	1	\$300,986	\$300,986	\$0	100.0%
Staud, Roland	1	\$2,157	\$2,157	\$0	100.0%
Striley, Catherine	2	\$85,914	\$85,914	\$0	100.0%
Subramony, Sankarasubramon	1	\$26,141	\$0	\$26,141	0.0%
Sweeney, Hugh	1	\$314,530	\$314,530	\$0	100.0%
Terada, Naohiro	1	\$0	\$0	\$0	0.0%
Tighe, Patrick	1	\$5,455	\$5,455	\$0	100.0%
Vaillancourt, David	1	\$0	\$0	\$0	0.0%
Vandenborne, Krista	20	\$8,693,253	\$5,873,028	\$2,820,225	67.6%
Vogel, Walter	3	\$661,095	\$661,095	\$0	100.0%
Walker, Ashby	1	\$495	\$495	\$0	100.0%
Walter, Glenn	2	\$1,045,730	\$1,045,730	\$0	100.0%
Wang, Yan	1	\$24,317	\$24,317	\$0	100.0%
Wheeler, Timothy	2	\$2,770	\$2,770	\$0	100.0%
Williamson, John	1	\$698	\$698	\$0	100.0%
Winesett, Steven	1	\$9,429	\$9,429	\$0	100.0%
Winter, Sandra	1	\$1,581	\$1,581	\$0	100.0%
Woods, Adam	2	\$55,927	\$55,927	\$0	100.0%
Wu, Samuel	1	\$41,556	\$41,556	\$0	100.0%
Yost, Richard	3	\$1,174,530	\$1,174,530	\$0	100.0%
Zhao, Jinying	4	\$5,170,559	\$5,170,559	\$0	100.0%
Zou, Fei	2	\$96,349	\$96,349	\$0	100.0%